Selection of appropriate type and intensity of lipid-lowering therapy

被引：5

作者：

Tikkanen, MJ ^{[1
]}

机构：

[1] UNIV HELSINKI, CENT HOSP, DEPT MED, DIV CARDIOL, SF-00290 HELSINKI, FINLAND

来源：

CURRENT OPINION IN LIPIDOLOGY | 1995年 / 6卷 / 06期

关键词：

D O I：

10.1097/00041433-199512000-00005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A wide consensus has been reached concerning the importance of lipid-lowering drug therapy in patients with dyslipidaemia with overt coronary heart disease. This consensus is also likely to be reflected in the more active treatment of other high-risk patient groups. The statin family of drugs has been tested in a large secondary prevention study, the Scandinavian Simvastatin Survival Study, and in angiographic trials. Their role in the treatment of hypercholesterolaemia and mixed hyperlipidaemia is increasing, whereas fibrates are increasingly limited to hypertriglyceridaemia.

引用

页码：360 / 364

页数：5

共 39 条

[1] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].

ANDERSON, TJ ;

MEREDITH, IT ;

YEUNG, AC ;

FREI, B ;

SELWYN, AP ;

GANZ, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493

[2] COMPARATIVE EFFECTS OF HMG-COA REDUCTASE INHIBITORS ON APO-B PRODUCTION IN THE CASEIN-FED RABBIT - ATORVASTATIN VERSUS LOVASTATIN [J].

AUERBACH, BJ ;

KRAUSE, BR ;

BISGAIER, CL ;

NEWTON, RS .

ATHEROSCLEROSIS, 1995, 115 (02) :173-180

[3]

BERGER ML, 1995, ATHEROSCLEROSIS SUPP, V115, pS96

[4]

BLACK D, 1994, ATHEROSCLEROSIS, V109, P88

[5] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].

BRADFORD, RH ;

SHEAR, CL ;

CHREMOS, AN ;

DUJOVNE, C ;

DOWNTON, M ;

FRANKLIN, FA ;

GOULD, AL ;

HESNEY, M ;

HIGGINS, J ;

HURLEY, DP ;

LANGENDORFER, A ;

NASH, DT ;

POOL, JL ;

SCHNAPER, H .

ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49

[6] CHOLESTEROL AND TOTAL MORTALITY - NEED FOR LARGER TRIALS [J].

COLLINS, R ;

KEECH, A ;

PETO, R ;

SLEIGHT, P ;

KJEKSHUS, J ;

WILHELMSEN, L ;

MACMAHON, S ;

SHAW, J ;

SIMES, J ;

BRAUNWALD, E ;

BURING, J ;

HENNEKENS, C ;

PFEFFER, M ;

SACKS, F ;

PROBSTFIELD, J ;

YUSUF, S ;

DOWNS, JR ;

GOTTO, A ;

COBBE, S ;

FORD, I ;

SHEPHERD, J .

BRITISH MEDICAL JOURNAL, 1992, 304 (6843) :1689-1689

[7] LOVASTATIN DECREASES COENZYME-Q LEVELS IN HUMANS [J].

FOLKERS, K ;

LANGSJOEN, P ;

WILLIS, R ;

RICHARDSON, P ;

XIA, LJ ;

YE, CQ ;

TAMAGAWA, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8931-8934

[8] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[9] PRAVASTATIN, LIPIDS, AND MAJOR CORONARY EVENTS [J].

FURBERG, CD ;

BYINGTON, RP ;

CROUSE, JR ;

ESPELAND, MA .

AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (15) :1133-1134

[10] EFFECT OF LOVASTATIN ON EARLY CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS [J].

FURBERG, CD ;

ADAMS, HP ;

APPLEGATE, WB ;

BYINGTON, RP ;

ESPELAND, MA ;

HARTWELL, T ;

HUNNINGHAKE, DB ;

LEFKOWITZ, DS ;

PROBSTFIELD, J ;

RILEY, WA ;

YOUNG, B .

CIRCULATION, 1994, 90 (04) :1679-1687

← 1 2 3 4 →